Posted: May 19, 2017

2017 - Reference list of hepatitis publications of the VHPB board members

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ.
Clin Gastroenterol Hepatol. 2017 Sep 22. pii: S1542-3565(17)31162-X. doi: 10.1016/j.cgh.2017.09.027.
State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs - United States, 2015-2016.
Campbell, C. A., L. Canary, N. Smith, E. Teshale, A. B. Ryerson and J. W. Ward.
MMWR Morb Mortal Wkly Rep. 2017; 66(18): 465-469.
Serological survey of hepatitis B immunity in healthcare workers in Catalonia (Spain).
Domínguez A, Urbiztondo L, Bayas JM, Borrás E, Broner S, Campins M, Costa J, Esteve M; Working Group for the Study of the Immune Status in Healthcare Workers of Catalonia.
Hum Vaccin Immunother. 2017 Feb;13(2):435-439. doi: 10.1080/21645515.2017.1264791..
Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization's global health sector strategy core indicators and scaling up key interventions.
Duffell EF, Hedrich D, Mardh O, Mozalevskis A.
Euro Surveill. 2017 Mar 2;22(9). pii: 30476. doi: 10.2807/1560-7917.ES.2017.22.9.30476.
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators.
Lancet Gastroenterol Hepatol. 2017; 2(5): 325-336.
Scaling-up HCV prevention and treatment interventions in rural United States- model projections for tackling an increasing epidemic.
Fraser, H., J. Zibbell, T. Hoerger, S. Hariri, C. Vellozzi, N. K. Martin, A. H. Kral, M. Hickman, J. W. Ward and P. Vickerman.
Addiction. 2017; 2(5): 325-336.
Sofosbuvir-Daclatasvir-Simeprevir plus Ribavirin in Direct-Acting Antiviral-Experienced Hepatitis C Patients.
Hezode, C., S. Fourati, S. Chevaliez, G. Scoazec, A. Soulier, A. Varaut, M. Francois, I. Ruiz, F. Roudot-Thoraval, A. Mallat and J. M. Pawlotsky.
Clin Infect Dis. 2017
Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review.
Hofstraat SHI, Falla AM, Duffell EF, Hahné SJM, Amato-Gauci AJ, Veldhuijzen IK, Tavoschi L.
Epidemiol Infect. 2017 Sep 11:1-13. doi: 10.1017/S0950268817001947.
Editorial on "What is a potentially damaging vaccination delay in children younger than 2 years?".
Kane MA, Roudot-Thoraval F, Guerin N, Papaevangelou V, Van Damme P; Viral Hepatitis Prevention Board.
Hum Vaccin Immunother. 2016 Aug 2;12(8):2053-2056.
Many European countries 'flying blind' in their efforts to eliminate viral hepatitis.
Lazarus JV, Safreed-Harmon K, Colombo M, Reic T, Schatz E, van Damme P; ACHIEVE Coalition..
Nat Rev Gastroenterol Hepatol. 2017 Jul 26;14(8):445-446. doi: 10.1038/nrgastro.2017.98..
Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses.
Lazarus JV, Safreed-Harmon K, Stumo SR, Jauffret-Roustide M, Maticic M, Reic T, Schatz E, Tallada J, Harris M; Hep-CORE Study Group.
NInt J Drug Policy. 2017 Sep;47:47-50. doi: 10.1016/j.drugpo.2017.05.054.
Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention.
Lemon SM, Ott JJ, Van Damme P, Shouval D.
J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32278-X. doi: 10.1016/j.jhep.2017.08.034.
Impact of hepatitis C oral therapy in portal hypertension..
Libânio D, Marinho RT.
World J Gastroenterol. 2017 Jul 14;23(26):4669-4674. doi: 10.3748/wjg.v23.i26.4669.
Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups.
Manor Y, Lewis M, Ram D, Daudi N, Mor O, Savion M, Kra-Oz Z, Shemer Avni Y, Sheffer R, Shouval D, Mendelson E.
J Infect Dis. 2016 Dec 23. pii: jiw611. doi: 10.1093/infdis/jiw611.
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.
Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).
Lancet Gastroenterol Hepatol. 2017 Oct 3. pii: S2468-1253(17)30284-4. doi: 10.1016/S2468-1253(17)30284-4.
Third edition of the Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV.
Maticic M.
Germs. 2017 Jun 1;7(2):60. doi: 10.18683/germs.2017.1109.
Late presentation of chronic viral hepatitis for medical care: a consensus definition.
Mauss, S., S. Pol, M. Buti, E. Duffell, C. Gore, J. V. Lazarus, H. L. der Grient, J. Lundgren, A. Mozalevskis, D. Raben, E. Schatz, S. Wiktor and J. K. Rockstroh.
BMC Med. 2017; 15(1): 92.
Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
McDonald, S. A., H. A. Innes, E. Aspinall, P. C. Hayes, M. Alavi, H. Valerio, D. J. Goldberg and S. J. Hutchinson.
J Viral Hepat. 2017; 24(4): 295-303.
High seroprevalence against hepatitis E virus in patients with chronic hepatitis C virus infection.
Mellgren, A., M. Karlsson, M. Karlsson, M. Lagging, R. Wejstal and H. Norder.
J Clin Virol. 2017; 88: 39-45.
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon, P., V. Bourcier, R. Layese, E. Audureau, C. Cagnot, P. Marcellin, D. Guyader, H. Fontaine, D. Larrey, V. De Ledinghen, D. Ouzan, F. Zoulim, D. Roulot, A. Tran, J. P. Bronowicki, J. P. Zarski, V. Leroy, G. Riachi, P. Cales, J. M. Peron, L. Alric, M. Bourliere, P. Mathurin, S. Dharancy, J. F. Blanc, A. Abergel, L. Serfaty, A. Mallat, J. D. Grange, P. Attali, Y. Bacq, C. Wartelle, T. Dao, Y. Benhamou, C. Pilette, C. Silvain, C. Christidis, D. Capron, B. Bernard-Chabert, D. Zucman, V. Di Martino, V. Thibaut, D. Salmon, M. Ziol, A. Sutton, S. Pol and F. Roudot-Thoraval.
Gastroenterology. 2017; 152(1): 142-156.e142.
The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
Nasrullah, M., D. Sergeenko, L. Gvinjilia, A. Gamkrelidze, T. Tsertsvadze, M. Butsashvili, D. Metreveli, L. Sharvadze, M. Alkhazashvili, S. Shadaker, J. W. Ward, J. Morgan and F. Averhoff.
MMWR Morb Mortal Wkly Rep 2017; 66(29): 773-776.
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo, A., R. Layese, P. Magistri, M. Gambato, M. Colledan, G. Magini, L. Miglioresi, A. Vitale, G. Vennarecci, C. D. Ambrosio, P. Burra, F. Di Benedetto, S. Fagiuoli, M. Colasanti, G. Maria Ettorre, A. Andreoli, U. Cillo, A. Laurent, S. Katsahian, E. Audureau, F. Roudot-Thoraval and C. Duvoux.
J Hepatol. 2017; 66(3): 552-559.
Effectiveness of hepatitis A vaccination as post-exposure prophylaxis.
Parron, I., C. Planas, P. Godoy, S. Manzanares-Laya, A. Martinez, M. R. Sala, S. Minguell, N. Torner, M. Jane and A. Dominguez.
Hum Vaccin Immunother. 2017; 13(2): 423-427.
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
Polaris Observatory HCV Collaborators.
Lancet Gastroenterol Hepatol. 2017; 2(3): 161-176.
Persistence of immunity 18-19 years after vaccination against hepatitis B in 2 cohorts of vaccinees primed as infants or as adolescents in Italy.
Romano, L., C. Galli, C. Tagliacarne, M. E. Tosti, C. Velati, L. Fomiatti, M. Chironna, R. C. Coppola, M. Cuccia, R. Mangione, F. Marrone, F. S. Negrone, A. Parlato, C. M. Zotti, A. Mele and A. R. Zanetti.
Hum Vaccin Immunother. 2017; 13(5): 981-985.
Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010.
Rosenberg, E. S., E. W. Hall, P. S. Sullivan, T. H. Sanchez, K. A. Workowski, J. W. Ward and D. Holtzman.
Clin Infect Dis. 2017
Performance of rapid diagnostic tests for the detection of anti-HBs in various patient populations.
Poiteau L, Soulier A, Roudot-Thoraval F, Hézode C, Challine D, Pawlotsky JM, Chevaliez S.
J Clin Virol. 2017 Sep 28;96:64-66. doi: 10.1016/j.jcv.2017.09.012.
Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro.
Rydell GE, Prakash K, Norder H, Lindh M.
Virology. 2017 Sep;509:67-70. doi: 10.1016/j.virol.2017.05.017. Epub 2017 Jun 10.
Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014.
Sanna A, Le Strat Y, Roudot-Thoraval F, Deuffic Burban S, Carrieri P, Delarocque-Astagneau E, Larsen C.
Euro Surveill. 2017 Jul 27;22(30). pii: 30582. doi: 10.2807/1560-7917.
Time course of hepatitis E-specific antibodies in adults.
Schemmerer M, Rauh C, Jilg W, Wenzel JJ.
J Clin Virol. 2017 Mar;88:39-45. doi: 10.1016/j.jcv.2017.01.005J Viral Hepat. 2017 Jan;24(1):75-79. doi: 10.1111/jvh.12621.
Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
Stone, J., N. K. Martin, M. Hickman, S. J. Hutchinson, E. Aspinall, A. Taylor, A. Munro, K. Dunleavy, E. Peters, P. Bramley, P. C. Hayes, D. J. Goldberg and P. Vickerman.
Addiction. 2017
Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review.
Stuurman, A. L., C. Marano, E. M. Bunge, L. De Moerlooze and D. Shouval.
Hum Vaccin Immunother. 2017; 13(3): 724-736.
Hepatitis B virus strains from Rwandan blood donors are genetically similar and form one clade within subgenotype A1.
Twagirumugabe, T., G. Swaibu, T. D. Walker, M. Lindh, J. B. Gahutu, T. Bergstrom and H. Norder.
BMC Infect Dis. 2017; 17(1): 32.
Low prevalence of hepatitis C virus RNA in blood donors with anti-hepatitis C virus reactivity in Rwanda.
Twagirumugabe T, Swaibu G, Bergström T, Walker TD, Gahutu JB, Norder H.
Transfusion. 2017 Oct;57(10):2420-2432. doi: 10.1111/trf.14204.
Seroepidemiology of HEV and HAV in two populations with different socio-economic levels and hygienic/sanitary conditions.
Zuin M, Caserta C, Romanò L, Mele A, Zanetti A, Cannatelli R, Giorgini A, Tagliacarne C, Amante A, Marcucci F, Battezzati PM.
Eur J Clin Microbiol Infect Dis 2017; 36: 479-485.
Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy.
Zanetti, A., M. G. Desole, L. Romano, A. d'Alessandro, M. Conversano, G. Ferrera, M. G. Panico, A. Tomasi, G. Zoppi, M. Zuliani, S. Thomas, B. Soubeyrand, C. Eymin and S. Lockhart.
Vaccine 2017; 35(32): 4034-4040.

Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review.

Stuurman AL, Marano C, Bunge EM, De Moerlooze L, Shouval D.

Hum Vaccin Immunother. 2017 Mar 4;13(3):724-736. Review.

Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review.

Carrillo-Santisteve P, Tavoschi L, Severi E, Bonfigli S, Edelstein M, Byström E, Lopalco P; ECDC HAV Expert Panel.

Lancet Infect Dis. 2017 Oct;17(10):e306-e319. doi: 10.1016/S1473-3099(17)30392-4. Epub 2017 Jun 20.

Third edition of the Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV. Matičič M. Germs. 2017 Jun 1;7(2):60. doi: 10.18683/germs.2017.1109. eCollection 2017 Jun.

Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. Lazarus JV, Safreed-Harmon K, Stumo SR, Jauffret-Roustide M, Maticic M, Reic T, Schatz E, Tallada J, Harris M; Hep-CORE Study Group. Int J Drug Policy. 2017 Sep;47:47-50. doi: 10.1016/j.drugpo.2017.05.054. Epub 2017 Jul 6.

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ.

Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426. doi: 10.1016/j.cgh.2017.09.027. Epub 2017 Sep 22.

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.

Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).

Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133. doi: 10.1016/S2468-1253(17)30284-4. Epub 2017 Oct 3

Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.

Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Zucman D, Di Martino V, Bagnis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir group.

Am Heart J. 2018 Apr;198:4-17. doi: 10.1016/j.ahj.2017.10.024. Epub 2017 Nov 7.

Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries.

Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, Ustianowski A, Duberg AS, Ruta S, Salkic NN, Husa P, Lazarevic I, Pineda JA, Pshenichnaya NY, Tsertswadze T, Matičič M, Puca E, Abuova G, Gervain J, Bayramli R, Ahmeti S, Koulentaki M, Kilani B, Vince A, Negro F, Sunbul M, Salmon D; ESGHV (part of ESCMID).

Antiviral Res. 2018 Feb;150:9-14. doi: 10.1016/j.antiviral.2017.12.001. Epub 2017 Dec 5.

Mortality Associated with Hepatobiliary Disease in Portugal between 2006 and 2012.

da Rocha MC, Marinho RT, Rodrigues T.

GE Port J Gastroenterol. 2018 Apr;25(3):123-131. doi: 10.1159/000484868. Epub 2017 Dec 6.

Is hepatitis B vaccination performed at infant and adolescent age able to provide long-term immunological memory? An observational study on healthcare students and workers in Florence, Italy.

Bini C, Grazzini M, Chellini M, Mucci N, Arcangeli G, Tiscione E, Bonanni P.

Hum Vaccin Immunother. 2018 Feb 1;14(2):450-455. doi: 10.1080/21645515.2017.1398297. Epub 2017 Dec 19.

Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.

Fourati S, Guedj J, Chevaliez S, Nguyen THT, Roudot-Thoraval F, Ruiz I, Soulier A, Scoazec G, Varaut A, Poiteau L, Francois M, Mallat A, Hézode C, Pawlotsky JM.

Aliment Pharmacol Ther. 2018 Mar;47(5):665-673. doi: 10.1111/apt.14478. Epub 2017 Dec 22.